Literature DB >> 23151052

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients.

Gilles Bonicelli1, Khadija Abdulkarim, Morgane Mounier, Peter Johansson, Cédric Rossi, Valérie Jooste, Björn Andreasson, Marc Maynadié, François Girodon.   

Abstract

Three hundred and twenty-seven patients from two population-based cohorts with an established diagnosis of polycythaemia vera were studied for prognostic risk factors for survival and leukaemia in a long-term survey. The relative survival (RS) was 72% and 46% at 10 and 20 years respectively, from the time of diagnosis. Multivariate analysis identified age >70 years, white blood cell count >13 × 10(9) /l and thrombo-embolism at diagnosis as independent risk factors. Patients with two or three of these factors had a 10 year RS of 26%, compared with 59% and 84% in patients with one and no risk factors, respectively. Age and leucocyte count are the main predicting factors for survival in polycythaemia vera.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23151052     DOI: 10.1111/bjh.12117

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

1.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

Review 2.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 3.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

4.  Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.

Authors:  Lukas Ronner; Nikolai Podoltsev; Jason Gotlib; Mark L Heaney; Andrew T Kuykendall; Casey O'Connell; Jamile Shammo; Angela G Fleischman; Robyn M Scherber; Ruben Mesa; Abdulraheem Yacoub; Cecelia Perkins; Shelby Meckstroth; Lindsey Behlman; Matthew Chiaramonte; Mahta Salehi; Kimia Ziadkhanpour; Hellen Nguyen; Olivia Siwoski; Annie Kwok Hung; Michelle Janania Martinez; Jenny Nguyen; Sagar Patel; Revathi Kollipara; Ami Dave; Megan Randall; Michael Grant; Mitchell Harrison; Paola Fernandez Soto; Douglas Tremblay; Ronald Hoffman; Erin Moshier; John Mascarenhas
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

5.  Vertebral artery thrombosis: a rare presentation of primary polycythaemia.

Authors:  H L Gul; S Y M Lau; D Chan-Lam; J-P Ng
Journal:  BMJ Case Rep       Date:  2014-05-26

6.  Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

Authors:  Julia T Geyer; Elizabeth Margolskee; Spencer A Krichevsky; Daniele Cattaneo; Leonardo Boiocchi; Paola Ronchi; Francesca Lunghi; Joseph M Scandura; Maurilio Ponzoni; Robert P Hasserjian; Umberto Gianelli; Alessandra Iurlo; Attilio Orazi
Journal:  Haematologica       Date:  2019-09-19       Impact factor: 9.941

7.  Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.

Authors:  Jingshi Wang; Yini Wang; Lin Wu; Xinkai Wang; Zhili Jin; Zhuo Gao; Zhao Wang
Journal:  Haematologica       Date:  2019-09-12       Impact factor: 9.941

Review 8.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

9.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Authors:  Leonardo Boiocchi; Umberto Gianelli; Alessandra Iurlo; Falko Fend; Irina Bonzheim; Daniele Cattaneo; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

10.  HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Authors:  Lanzhu Yue; Vasundhara Sharma; Nathan P Horvat; Afua A Akuffo; Matthew S Beatty; Cem Murdun; Christelle Colin; Julia M R Billington; William E Goodheart; Eva Sahakian; Ling Zhang; John J Powers; Narmin E Amin; Que T Lambert-Showers; Lancia N Darville; Javier Pinilla-Ibarz; Gary W Reuther; Kenneth L Wright; Chiara Conti; Jennifer Y Lee; Xiaozhang Zheng; Pui Yee Ng; Matthew W Martin; C Gary Marshall; John M Koomen; Ross L Levine; Amit Verma; H Leighton Grimes; Eduardo M Sotomayor; Zonghong Shao; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.